The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Por Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Publicado no Haematologica (2015)